These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 8963770)

  • 41. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.
    Christiansen D; Milland J; Thorley BR; McKenzie IF; Loveland BE
    Eur J Immunol; 1996 Mar; 26(3):578-85. PubMed ID: 8605924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
    Clayton A; Harris CL; Court J; Mason MD; Morgan BP
    Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanism of host cell protection from complement in murine cytomegalovirus (CMV) infection: identification of a CMV-responsive element in the CD46 promoter region.
    Nomura M; Kurita-Taniguchi M; Kondo K; Inoue N; Matsumoto M; Yamanishi K; Okabe M; Seya T
    Eur J Immunol; 2002 Oct; 32(10):2954-64. PubMed ID: 12355449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement regulation.
    Meri S; Jarva H
    Vox Sang; 1998; 74 Suppl 2():291-302. PubMed ID: 9704459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease.
    Davies ME; Horner A; Loveland BE; McKenzie IF
    Scand J Rheumatol; 1994; 23(6):316-21. PubMed ID: 7528443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection.
    Lazzeri M; Mora M; Mulder LC; Marsicano G; Marinucci G; Boschi M; Bruzzone P; Alfani D; Cortesini R; Rossini M
    J Urol; 1998 Apr; 159(4):1364-9. PubMed ID: 9507885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The complement system and adaptive immunity.
    Fearon DT
    Semin Immunol; 1998 Oct; 10(5):355-61. PubMed ID: 9799710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms by which the erythrocyte protects itself from complement damage.
    Nicholson-Weller A; Halperin JA
    Prog Clin Biol Res; 1989; 297():263-70; discussion 270-1. PubMed ID: 2479950
    [No Abstract]   [Full Text] [Related]  

  • 49. The regulation of the complement system: insights from genetically-engineered mice.
    Turnberg D; Botto M
    Mol Immunol; 2003 Sep; 40(2-4):145-53. PubMed ID: 12914820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunologic tests: Membrane cofactor protein (MCP, CD46)].
    Shingai M; Seya T
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():95-7. PubMed ID: 16111198
    [No Abstract]   [Full Text] [Related]  

  • 51. Cell surface proteins reacting with activated complement components.
    Becherer JD; Alsenz J; Servis C; Myones BL; Lambris JD
    Complement Inflamm; 1989; 6(3):142-65. PubMed ID: 2526003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacological effects on the complement system. Possibilities and limitations of anti-inflammatory therapy].
    Kirschfink M
    Dtsch Med Wochenschr; 1995 Aug; 120(31-32):1087-90. PubMed ID: 7641591
    [No Abstract]   [Full Text] [Related]  

  • 53. Complement and cellular triggering reactions. Introductory remarks.
    Hugli TE
    Fed Proc; 1984 Jul; 43(10):2540-2. PubMed ID: 6234185
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparative analysis of human DAF expression in the tissues of transgenic pigs and man.
    Cozzi E; Langford GA; Wright L; Tucker A; Yannoutsos N; Richards A; Rosengard A; Elsome K; Lancaster R; White DJ
    Transplant Proc; 1995 Feb; 27(1):319-20. PubMed ID: 7533397
    [No Abstract]   [Full Text] [Related]  

  • 55. Production of pigs transgenic for human regulators of complement activation using YAC technology.
    Langford GA; Cozzi E; Yannoutsos N; Lancaster R; Elsome K; Chen P; White DJ
    Transplant Proc; 1996 Apr; 28(2):862-3. PubMed ID: 8623438
    [No Abstract]   [Full Text] [Related]  

  • 56. Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection.
    Seya T
    Microbiol Immunol; 1995; 39(5):295-305. PubMed ID: 7565169
    [No Abstract]   [Full Text] [Related]  

  • 57. Expression and localization of proteins of the complement system in human skin.
    Dovezenski N; Billetta R; Gigli I
    J Clin Invest; 1992 Nov; 90(5):2000-12. PubMed ID: 1385479
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Into the third century of complement research.
    Morgan BP; Daha M; Meri S; Nicholson-Weller A
    Immunol Today; 2000 Dec; 21(12):603-5. PubMed ID: 11188795
    [No Abstract]   [Full Text] [Related]  

  • 59. Structure and flexibility of the multiple domain proteins that regulate complement activation.
    Kirkitadze MD; Barlow PN
    Immunol Rev; 2001 Apr; 180():146-61. PubMed ID: 11414356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1.
    Hourcade D; Liszewski MK; Krych-Goldberg M; Atkinson JP
    Immunopharmacology; 2000 Aug; 49(1-2):103-16. PubMed ID: 10904110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.